$150M Settlement Receives Final Approval In Flonase Sham Litigation Case

$150M Settlement Receives Final Approval In Flonase Sham Litigation Case

PHILADELPHIA - A federal judge in Pennsylvania on June 14 granted final approval to a $150 million cash settlement between Flonase manufacturer GlaxoSmithKline PLC (GSK) and a certified class of 33 direct purchasers on the direct purchasers' claims that GSK filed a series of sham citizen petitions with the Food and Drug Administration to delay the entry of a generic version of Flonase into the market in violation of Section 2 of the Sherman Act (In re Flonase Antitrust Litigation $(Direct Purchaser Actions$), No. 08-3149, E.D. Pa.; 2013 U.S. Dist. LEXIS 83976).

Find full version on lexis Advance®
Access this news story on lexis.com®